- Trials with a EudraCT protocol (414)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
414 result(s) found for: Acute Lymphoblastic Leukemia (ALL).
Displaying page 6 of 21.
EudraCT Number: 2004-001647-30 | Sponsor Protocol Number: ESPHALL | Start Date*: 2004-04-28 | |||||||||||
Sponsor Name:A.I.E.O.P. - ASSOCIAZIONE ITALIANA EMATOLOGIA ONCOLOGIA PEDIATRICA | |||||||||||||
Full Title: An open-label study to evaluate the safety and efficacy of IMATINIB with chemotherapy in pediatric patients with Ph+/BCR-ABL+ acute lymphoblastic leukemia (Ph+ALL) | |||||||||||||
Medical condition: Children and adolescents aged 1-17 years at diagnosis, with Ph+ALL | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004251-23 | Sponsor Protocol Number: LAL2317 | Start Date*: 2018-04-26 | |||||||||||
Sponsor Name:FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS | |||||||||||||
Full Title: National Treatment Program with Sequential Chemotherapy and Blinatumomab to Improve Minimal Residual Disease Response and Survival in Philadelphia Chromosome-Negative B-Cell | |||||||||||||
Medical condition: Acute Lymphoblastic Leukemia Philadelphia Chromosome Negative (Ph-) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000074-19 | Sponsor Protocol Number: GCP#03.01.020 | Start Date*: 2014-10-24 | |||||||||||||||||||||||||||||||
Sponsor Name:Gamida Cell Ltd | |||||||||||||||||||||||||||||||||
Full Title: Full title of the trial: Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells, in Adolescents and Adult Patients with Hematologic... | |||||||||||||||||||||||||||||||||
Medical condition: High risk haematological malignancies | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: ES (Completed) IT (Completed) NL (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-003006-32 | Sponsor Protocol Number: ALL2418 | Start Date*: 2019-07-08 | ||||||||||||||||
Sponsor Name:FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS | ||||||||||||||||||
Full Title: "A Phase IIA Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin (IO) in Adult Patients with B-Cell Acute Lymphoblastic Leukemia with positive Minimal Residual Disease before any Hemato... | ||||||||||||||||||
Medical condition: Acute B-cell Lymphoblastic Leukemia with minimal residual positive disease prior to haematopoietic stem cell transplantation in adult patients | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003517-17 | Sponsor Protocol Number: ALL2518 | Start Date*: 2019-09-26 | |||||||||||
Sponsor Name:FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS | |||||||||||||
Full Title: Asparaginase Activity Monitoring (AAM) in adult patients with Acute Lymphoblastic Leukemia (ALL). | |||||||||||||
Medical condition: Adult patients, aged between 18 and 65, diagnosed with Acute Ph Lymphoblastic Leukemia negative (LAL Ph-) untreated, with a favorable impact on the prognosis. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000557-88 | Sponsor Protocol Number: Anti-CD19-ALL | Start Date*: 2022-11-14 | |||||||||||
Sponsor Name:University Hospital Tuebingen | |||||||||||||
Full Title: A Prospective Phase I/II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Tafasitamab (MOR00208) in Pediatric Patients with Relapsed or Refractory Acute B Lineage L... | |||||||||||||
Medical condition: B-lineage (CD19 positive) ALL (B, pro-B, pre-B or c-ALL) refractory to standard treatment or with relapsed disease | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-016075-30 | Sponsor Protocol Number: GIMEMA LAL1308 | Start Date*: 2010-07-09 | |||||||||||
Sponsor Name:G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL`ADULTO | |||||||||||||
Full Title: Therapy of the Young Adult Acute Lymphoblastic Leukemia (ALL): treatment intensification of the pediatric protocol AIEOP LLA-2000 | |||||||||||||
Medical condition: Acute Lymphoblastic Leukemia (ALL) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-004884-20 | Sponsor Protocol Number: BRD 08/7-J | Start Date*: 2008-12-15 | |||||||||||||||||||||
Sponsor Name:CHU de Nantes | |||||||||||||||||||||||
Full Title: Protocole Clinique de Phase II multicentrique non randomisé évaluant l’efficacité, la tolérance et la toxicité d’un conditionnement à intensité réduite combinant Clofarabine (Evoltra) + Busulfan IV... | |||||||||||||||||||||||
Medical condition: LAL Leucémie Aiguë lymphoblastique LAM Leucémie Aiguë Myéloblastique MDS Syndrome MyéloDysplasique | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-012718-35 | Sponsor Protocol Number: Loulla001 | Start Date*: 2010-05-05 | |||||||||||
Sponsor Name:Only For Children Pharmaceuticals | |||||||||||||
Full Title: An open-label, randomised crossover pharmacokinetic, palatability and safety study to assess the bioavailability of a new 6MP oral liquid formulation by comparison to a currently registered 6MP 50 ... | |||||||||||||
Medical condition: Acute Lymphoblastic Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) DE (Ongoing) DK (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002761-35 | Sponsor Protocol Number: LAL1811 | Start Date*: 2012-11-14 | |||||||||||
Sponsor Name:INCYTE Biosciences International Sarl | |||||||||||||
Full Title: Trattamento di prima linea della Leucemia Linfoblastica Acuta (LLA) Philadelphia positiva (Ph+)/BCR/ABL+ con un nuovo potente inibitore delle Tirosin-chinasi (TKI), AP24534 (Ponatinib). Studio mult... | |||||||||||||
Medical condition: Ph positive (Ph+)/Bcr-Abl positive Acute Lymphoblastic Leukemia (ALL) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003902-28 | Sponsor Protocol Number: CAMN107A2409 | Start Date*: 2013-03-05 | |||||||||||||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||||||||||||
Full Title: An open label, multi-center nilotinib roll-over protocol for patients who have completed a previous Novartis-sponsored nilotinib study and are judged by the investigator to benefit from continued ... | |||||||||||||||||||||||
Medical condition: Patients who are on nilotinib treatment in a Novartis-sponsored, Oncology Global Development & Global Medical Affairs study and are benefiting from the treatment as judged by the investigator. All ... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: AT (Completed) IT (Completed) ES (Ongoing) HU (Completed) NL (Completed) GB (GB - no longer in EU/EEA) SK (Completed) SE (Completed) FR (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-002331-41 | Sponsor Protocol Number: HaploMUDStudy | Start Date*: 2019-09-27 | |||||||||||
Sponsor Name:University Medical Center Hamburg - Eppendorf | |||||||||||||
Full Title: Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients with Acute Leukemia with Identical GVHD Prophylaxis – A Randomized Prospective European Trial | |||||||||||||
Medical condition: Acute Myeloid Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-004950-25 | Sponsor Protocol Number: D-00272-CT2014001 | Start Date*: 2008-01-06 | ||||||||||||||||
Sponsor Name:Cell Medica Ltd | ||||||||||||||||||
Full Title: WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study | ||||||||||||||||||
Medical condition: Acute Myeloid Leukaemia and Chronic Myeloid Leukaemia in adults. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-000297-38 | Sponsor Protocol Number: CL1-68587-003 | Start Date*: 2016-06-22 | ||||||||||||||||
Sponsor Name:Institut de Recherches Internationales Servier (I.R.I.S) | ||||||||||||||||||
Full Title: Long-term follow-up study of patients who have previously been exposed to UCART19 / ALLO-501 (allogeneic engineered T-cells expressing a lentiviral-based anti-CD19 chimeric antigen receptor) | ||||||||||||||||||
Medical condition: Advanced lymphoid malignancies | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Ongoing) ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004674-17 | Sponsor Protocol Number: NL59901.078.17 | Start Date*: 2017-10-17 | |||||||||||
Sponsor Name:Princess Máxima Center for Pediatric Oncology | |||||||||||||
Full Title: A pilot study to test the feasibility, safety and efficacy of the addition of the BiTE antibody Blinatumomab to the Interfant-06 backbone in infants with MLL-rearranged acute lymphoblastic leukemia... | |||||||||||||
Medical condition: Acute Lymphoblastic Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) AT (Completed) BE (Completed) DK (Completed) DE (Completed) CZ (Completed) FR (Ongoing) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004672-21 | Sponsor Protocol Number: CR-AIR-009 | Start Date*: 2017-06-15 | |||||||||||||||||||||||||||||||
Sponsor Name:Kiadis Pharma Netherlands B.V. | |||||||||||||||||||||||||||||||||
Full Title: A Phase III, multicenter, randomized controlled study to compare safety and efficacy of a haploidentical HSCT and adjunctive treatment with ATIR101, a T-lymphocyte enriched leukocyte preparation de... | |||||||||||||||||||||||||||||||||
Medical condition: Patients with a hematologic malignancy (AML, ALL, or MDS) who are eligible for a haploidentical HSCT | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) DE (Prematurely Ended) ES (Completed) PT (Completed) NL (Prematurely Ended) HR (Completed) FR (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-000999-26 | Sponsor Protocol Number: 13-006 | Start Date*: 2014-09-20 | |||||||||||||||||||||
Sponsor Name:Jazz Pharmaceuticals, Inc. | |||||||||||||||||||||||
Full Title: An Open-Label, Single-Arm, Multicenter Pharmacokinetic Study of Intramuscular Erwinaze® (asparaginase Erwinia chrysanthemi)/Erwinase® (crisantaspase) Administered Following Hypersensitivity to E. c... | |||||||||||||||||||||||
Medical condition: 1) Acute Lymphoblastic Leukemia 2) Lymphoblastic Lymphoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: ES (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-004761-17 | Sponsor Protocol Number: SG033-0003 | Start Date*: 2008-05-14 | |||||||||||
Sponsor Name:Seattle Genetics, Inc. | |||||||||||||
Full Title: A Phase IIB, Randomized, Double-Blinded, Placebo-Controlled Study of Low Dose Cytarabine and Lintuzumab Compared to Low Dose Cytarabine and Placebo in Patients 60 Years of Age and Older with Previo... | |||||||||||||
Medical condition: acute myeloid leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Prematurely Ended) HU (Prematurely Ended) AT (Completed) PL (Prematurely Ended) BG (Prematurely Ended) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003191-12 | Sponsor Protocol Number: TUD-2DAUNO-058 | Start Date*: 2014-01-31 | ||||||||||||||||||||||||||
Sponsor Name:Technische Universität Dresden | ||||||||||||||||||||||||||||
Full Title: Randomized comparison between two dose levels of daunorubicin and between one versus two cycles of in-duction therapy for adult patients with acute myeloid leukemia ≤65 years | ||||||||||||||||||||||||||||
Medical condition: Newly diagnosed AML other than acute promyelocytic leukemia (APL) according to WHO criteria, i.e. bone marrow aspirate or biopsy must contain ≥20% blasts of all nucleated cells or differential bloo... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: DE (Completed) CZ (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-015118-23 | Sponsor Protocol Number: DASA-TRAS | Start Date*: 2010-01-05 | |||||||||||
Sponsor Name:GETH | |||||||||||||
Full Title: ESTUDIO PILOTO FASE II MULTICÉNTRICO, NO ALEATORIZADO PARA EVALUAR LA EFICACIA Y SEGURIDAD DE DASATINIB TRAS TRASPLANTE ALOGÉNICO DE PROGENITORES HEMOPOYÉTICOS EN PACIENTES CON LEUCEMIA AGUDA LINFO... | |||||||||||||
Medical condition: Evaluar la eficacia del mantenimiento con dasatinib en términos de Supervivencia Libre de Enfermedad a 2 años, estimado según curvas de Kaplan-Meier, en pacientes con Leucemia Linfoblástica Aguda P... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
